Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

Early BP can appear very similar to conditions seen in urticarial dermatitis. Patients with the urticarial form of BP may never develop typical BP bullae, but continue to exhibit skin lesions ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.

France’s Sanofi and Tarrytown, N.Y.-based Regeneron said Friday that the FDA gave the green light for Dupixent as a treatment of adult patients with bullous pemphigoid, a skin disease that ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...